Skip to main content
[Preprint]. 2023 Mar 31:2023.03.30.23287923. [Version 1] doi: 10.1101/2023.03.30.23287923

Figure 1. SARS-CoV-2 neutralization to the original infecting strain and cross-neutralization to subsequent viral variants.

Figure 1.

Ex vivo antibody neutralization of the original SARS-CoV-2 virus and subsequent variants approximately 1 month (A, N=69), 2 months (B, N=115), and 4 months (C, N=119) following acute infection for all participants. Subgroup analysis of cross-neutralization in an expanded Omicron sub variant panel (N=16) in a subset of participants that had samples across all timepoints with either high or negative neutralization to BA.5 (D). Most samples collected prior to SARS-CoV-2 vaccination and prior to the emergence of Delta and Omicron variants. Bars represent mean antibody (Ab) infectious dose 50% (ID50) values and 95% confidence intervals (* P<0.05, ** P<0.01, ***P<0.001 by two-sided Freidman test adjusted for multiple comparisons).